171 related articles for article (PubMed ID: 27257808)
41. Splenic granulomatous lesions in immunocompetent pediatric patients with visceral leishmaniasis.
Fretzayas A; Moustaki M; Kitsiou S; Mathioudakis J; Karpathios T
Scand J Infect Dis; 2001; 33(11):865-7. PubMed ID: 11760174
[TBL] [Abstract][Full Text] [Related]
42. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
43. Visceral Leishmaniasis in Southwestern Iran: A Retrospective Clinico-Hematological Analysis of 380 Consecutive Hospitalized Cases (1999-2014).
Sarkari B; Naraki T; Ghatee MA; Abdolahi Khabisi S; Davami MH
PLoS One; 2016; 11(3):e0150406. PubMed ID: 26942443
[TBL] [Abstract][Full Text] [Related]
44. The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting.
Vega JC; Sanchez BF; Montero LM; Montaña R; Mahecha Mdel P; Dueñes B; Baron AR; Reithinger R
Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):703-6. PubMed ID: 19059616
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan.
Griekspoor A; Sondorp E; Vos T
Health Policy Plan; 1999 Mar; 14(1):70-6. PubMed ID: 10351471
[TBL] [Abstract][Full Text] [Related]
47. Cost of visceral leishmaniasis care in Brazil.
de Carvalho IPSF; Peixoto HM; Romero GAS; de Oliveira MRF
Trop Med Int Health; 2017 Dec; 22(12):1579-1589. PubMed ID: 29078015
[TBL] [Abstract][Full Text] [Related]
48. Fulminant hepatitis in an Italian infant with visceral leishmaniasis.
di Martino L; Vajro P; Nocerino A; Scotti S; Napolitano G; Vegnente A
Trans R Soc Trop Med Hyg; 1992; 86(1):34. PubMed ID: 1566298
[No Abstract] [Full Text] [Related]
49. The household costs of visceral leishmaniasis care in south-eastern Nepal.
Uranw S; Meheus F; Baltussen R; Rijal S; Boelaert M
PLoS Negl Trop Dis; 2013; 7(2):e2062. PubMed ID: 23469298
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for relapse of visceral leishmaniasis in Georgia.
Kajaia M; Morse DL; Kamkamidze G; Butsashvili M; Chubabria G; Zenaishvili O; Kokaia N; McNutt LA
Trop Med Int Health; 2011 Feb; 16(2):186-92. PubMed ID: 21143353
[TBL] [Abstract][Full Text] [Related]
51. [N-methyl glucamine antimoniate or Glucantime].
Rapp C; Simon F; Dordain ML
Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
[No Abstract] [Full Text] [Related]
52. Treatment of visceral leishmaniasis.
Ozsoylu S
Am J Dis Child; 1992 Sep; 146(9):1021. PubMed ID: 1514542
[No Abstract] [Full Text] [Related]
53. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
54. [Association of acute lymphoblastic leukaemia and visceral leishmaniasis].
Nafil H; Tazi I; Mahmal L
Ann Biol Clin (Paris); 2011; 69(6):729-31. PubMed ID: 22123576
[TBL] [Abstract][Full Text] [Related]
55. Rapid clearance of circulating Leishmania kinetoplast DNA after treatment of visceral leishmaniasis.
Disch J; Oliveira MC; Orsini M; Rabello A
Acta Trop; 2004; 92(3):279-83. PubMed ID: 15533299
[TBL] [Abstract][Full Text] [Related]
56. Visceral childhood leishmaniasis in southern Turkey: experience of twenty years.
Dursun O; Erişir S; Yeşilipek A
Turk J Pediatr; 2009; 51(1):1-5. PubMed ID: 19378883
[TBL] [Abstract][Full Text] [Related]
57. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
[TBL] [Abstract][Full Text] [Related]
58. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
[TBL] [Abstract][Full Text] [Related]
59. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)].
Barthet M; Brunet P; Bernard JC; Dussol B; Rodor F; Jouglard J; Berland Y; Sahel J
Gastroenterol Clin Biol; 1994; 18(1):90-2. PubMed ID: 8187998
[No Abstract] [Full Text] [Related]
60. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
Olliaro P; Darley S; Laxminarayan R; Sundar S
Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
